Epigenetic-related Gene-based Prognostic Model Construction and Validation in Prostate Adenocarcinoma

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 May 23

PMID 38779031

Authors

Youyou Li

Chao Li

Longxiang Wu

Jiaren Li

Yu Gan

Shuo Tan

Lei Zhou

Wei Xiong

Liang Zhou

Cheng Li

Jiahao Liu

Dingwen Liu

Yichuan Wang

Yunlong Fu

Kun Yao

Long Wang

Affiliations

Soon will be listed here.

Abstract

Prostate adenocarcinoma (PRAD), driven by both genetic and epigenetic factors, is a common malignancy that affects men worldwide. We aimed to identify and characterize differentially expressed epigenetic-related genes (ERGs) in PRAD and investigate their potential roles in disease progression and prognosis. We used PRAD samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to identify prognosis-associated ERGs. Thirteen ERGs with two distinct expression profiles were identified through consensus clustering. Gene set variation analysis highlighted differences in pathway activities, particularly in the Hedgehog and Notch pathways. Higher epigenetic scores correlated with favorable prognosis and improved immunotherapeutic response. Experimental validation underscored the importance of CBX3 and KAT2A, suggesting their pivotal roles in PRAD. This study provides crucial insights into the epigenetic scoring approach and presents a promising prognostic tool, with CBX3 and KAT2A as key players. These findings pave the way for targeted and personalized interventions for the treatment of PRAD.

References

Lopez J, Anazco-Guenkova A, Monteagudo-Garcia O, Blanco S . Epigenetic and Epitranscriptomic Control in Prostate Cancer. Genes (Basel). 2022; 13(2). PMC: 8872343. DOI: 10.3390/genes13020378. View

Mortensen M, Hoyer S, Lynnerup A, Orntoft T, Sorensen K, Borre M . Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 2015; 5:16018. PMC: 4629186. DOI: 10.1038/srep16018. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Koinis F, Chantzara E, Samarinas M, Xagara A, Kratiras Z, Leontopoulou V . Emerging Role of YAP and the Hippo Pathway in Prostate Cancer. Biomedicines. 2022; 10(11). PMC: 9687800. DOI: 10.3390/biomedicines10112834. View

Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G . Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(9):1119-1134. DOI: 10.1016/j.annonc.2020.06.011. View

Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov J, Tamayo P . The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2016; 1(6):417-425. PMC: 4707969. DOI: 10.1016/j.cels.2015.12.004. View

Farsetti A, Illi B, Gaetano C . How epigenetics impacts on human diseases. Eur J Intern Med. 2023; 114:15-22. DOI: 10.1016/j.ejim.2023.05.036. View

Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P . Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020; 12(1):21. PMC: 7045518. DOI: 10.1186/s13073-020-0721-z. View

He Y, Xu W, Xiao Y, Huang H, Gu D, Ren S . Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022; 7(1):198. PMC: 9232569. DOI: 10.1038/s41392-022-01042-7. View

10.

Bergengren O, Pekala K, Matsoukas K, Fainberg J, Mungovan S, Bratt O . 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 2023; 84(2):191-206. PMC: 10851915. DOI: 10.1016/j.eururo.2023.04.021. View

11.

Mourkioti I, Angelopoulou A, Belogiannis K, Lagopati N, Potamianos S, Kyrodimos E . Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer. Cells. 2022; 11(15). PMC: 9367915. DOI: 10.3390/cells11152449. View

12.

Pritchard C, Mateo J, Walsh M, De Sarkar N, Abida W, Beltran H . Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016; 375(5):443-53. PMC: 4986616. DOI: 10.1056/NEJMoa1603144. View

13.

Houlahan K, Shiah Y, Gusev A, Yuan J, Ahmed M, Shetty A . Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat Med. 2019; 25(10):1615-1626. PMC: 7418214. DOI: 10.1038/s41591-019-0579-z. View

14.

Zong Y, Huang J, Sankarasharma D, Morikawa T, Fukayama M, Epstein J . Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci U S A. 2012; 109(50):E3395-404. PMC: 3528570. DOI: 10.1073/pnas.1217982109. View

15.

Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K . Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022; 7(1):95. PMC: 8948217. DOI: 10.1038/s41392-022-00934-y. View

16.

Goel S, Bhatia V, Biswas T, Ateeq B . Epigenetic reprogramming during prostate cancer progression: A perspective from development. Semin Cancer Biol. 2021; 83:136-151. PMC: 7612861. DOI: 10.1016/j.semcancer.2021.01.009. View

17.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

18.

Kukkonen K, Taavitsainen S, Huhtala L, Uusi-Makela J, Granberg K, Nykter M . Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. Cancers (Basel). 2021; 13(13). PMC: 8268970. DOI: 10.3390/cancers13133325. View

19.

Valdez-Vargas A, Sanchez-Lopez H, Badillo-Santoyo M, Maldonado-Valadez R, Manzo-Perez B, Perez-Abarca V . Recurrence rate of localized prostate cancer after radical prostatectomy according to D'amico risk classification in a tertiary referral hospital: association study. Cir Cir. 2021; 89(4):520-527. DOI: 10.24875/CIRU.200007601. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View